Country, language and currency
- Social bookmarks:
- Testimonials
-
Well, I must apologize - I thought surely you were scamming me. But, all of
a sudden, my mailbox overflows. I received one order on Thursday, 8 June,
and then another on Saturday, 10 June. Almost 1 month from our first
effort, but the postal service must be the culprits. With this double
supply, you are now going to have to send me a couple of women, so the meds
don't go to waste. How can we make this right? What would you like me to
do? Thanks. I hope only good karma comes to you.
- Curt
Read more »
-
- Dutasteride May Slow Prostate Cancer Progression - OncLive
- OncLiveDutasteride May Slow Prostate Cancer ProgressionOncLiveDutasteride, a 5α-reductase inhibitor approved for the treatment of benign prostatic hyperplasia, may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy, as well as the need to start
- Coronary Artery Disease May Boost Risk of Prostate Cancer - OncLive
- OncLiveCoronary Artery Disease May Boost Risk of Prostate CancerOncLiveThe 4-year, phase III REDUCE study evaluated the 5α-reductase inhibitor dutasteride, 0
- 5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance - OncLive
- OncLive5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active SurveillanceOncLiveHe added that these findings are supported by the double-blind, placebo-controlled Reduction by Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM) trial, which was recently published in The Lancet
- New Therapy Is Essential for Men with Prostate Enlargement As Medications Have ... - Seattle Post Intelligencer
- New Therapy Is Essential for Men with Prostate Enlargement As Medications Have
- Pricing pressures and Middle East unrest hit GSK profits - Pharma Times
- Pricing pressures and Middle East unrest hit GSK profitsPharma TimesThe Avodart (dutasteride) franchise, for the treatment of benign prostatic hyperplasia, increased 11% to £186 million, while Lamictal (lamotrigine) for seizures and bipolar disorder, grew 29% to £148 million